Themis Medicare Limited (IN:THEMISMED)
:THEMISMED
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹179.25
Previous CloseN/A
Volume256.77K
Average Volume (3M)6.87K
Market Cap
₹7.28B
Enterprise Value₹8.17B
Total Cash (Recent Filing)₹189.59M
Total Debt (Recent Filing)₹955.64M
Price to Earnings (P/E)22.9
Beta1.73
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)1.10
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-1.45
Price to Book (P/B)3.39
Price to Sales (P/S)3.37
P/FCF Ratio70.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsConsistent top-line gains paired with high gross margins indicate durable product demand and manufacturing cost efficiency. This combination supports reinvestment in capacity and R&D, sustains operating leverage as volumes scale, and underpins long-term margin resilience versus purely commoditized peers.
Stable Balance Sheet And Managed LeverageA healthy equity ratio and controlled debt levels provide financial flexibility for capex, manufacturing scale-up, and potential partnerships without excessive refinancing risk. Managed leverage supports resilience to industry cyclicality and funds strategic investments with limited strain on liquidity.
Improving Operating Cash Flow And FCF RecoveryA recovery in operating cash flow and free cash flow signals improving cash generation from core operations, enabling self-funded capex and debt servicing. Sustained cash conversion would strengthen financial independence, support contract manufacturing growth and reduce reliance on external funding.
Bears Say
Recent Reported Revenue ContractionA sizable recent revenue decline is a material structural risk if it reflects lost market share, pricing pressure, or product de-listings. Sustained revenue weakness can erode operating leverage, compress margins, and require margin restoration via cost cuts or larger reinvestment cycles to regain growth.
Volatile Net Profit MarginPersistent volatility in net margins reduces predictability of earnings and free cash flow. For a pharma manufacturer, this may reflect pricing pressure, input cost swings, or mix shifts toward lower-margin products, complicating budgeting and long-term investment planning.
Inconsistent Cash ConversionInconsistent conversion of accounting profits into cash can limit the company's ability to fund capex, pay down debt, or pursue M&A without external financing. Structural issues in receivables, inventory or working-capital management would weaken financial flexibility over multiple quarters.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹179.25 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹7.28B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is May 27, 2026 which is in 52 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on Feb 13, 2026. The company reported ₹1.096 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.096.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.48%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹1.096 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.41%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was incorporated in 1969 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Kopran Limited
―
Lincoln Pharmaceuticals Ltd
―
Wanbury Limited
―